SUMMARY
Background Pembrolizumab improved survival of patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this phase 2 trial were to determine if pembrolizumab administered to patients with resectable locally advanced, human papillomavirus (HPV)-unrelated HNSCC would be safe, result in pathologic tumor response (pTR), and lower the relapse rate.
Methods Neoadjuvant pembrolizumab (200 mg) was administered 2-3 weeks before surgery. Resection of the primary tumor and involved/at-risk nodes was performed. Post-operative (chemo) radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) were to receive adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10-49%), and pTR-2 (≥50%). Co-primary endpoints were pTR-2 among all patients, and one-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 expression and T-cell infiltration with pTR were assessed, and tumor clonal dynamics were evaluated. Analyses were done per protocol. This trial is registered with ClinicalTrials.gov(NCT02296684), and is ongoing but closed to accrual.
Findings Between June 30, 2015, and March 30, 2018, 36 patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3-4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). pTR ≥10% correlated with baseline tumor PD-L1 expression, immune infiltrate, and IFN-γ pathway activity. Matched sample analysis showed compensatory upregulation of multiple immune inhibitory checkpoints in patients with pTR-0, and confirmed that clonal loss occurred in some patients. The one-year relapse rate among the eighteen patients with high-risk pathology was 16.7% (95%CI: 3.6-41.4%).
Conclusions Among patients with locally advanced, HPV-unrelated HNSCC, neoadjuvant pembrolizumab was safe, and resulted in pTR-1 or pTR-2 in 44% of patients. The one-year relapse rate in patients with high-risk-pathology was lower than historical.
Funding Merck, NCI, NIDCR, NHGRI and The V Foundation.
- pembrolizumab
- head and neck squamous-cell carcinoma
- neoadjuvant therapy
Competing Interest Statement
RU is on the scientific advisory board at Merck. RIH receives research support and does consulting for BMS, Merck, Astra Zeneca, Pfizer, and Celgene. GJH receives research support and does consulting for BMS, Merck, Astra Zeneca, Pfizer, and Celgene. JS consulted and/ or received grants from Bristol-Myers Squibb, Merck, AstraZeneca, Debiopharm, Nanobiotix, Regeneron and Tilos Therapeutics. RU and DA report research funding from Merck as part of the work under consideration for publication. DA reports personal fees for advisory role/consulting from Pfizer, Eli Lilly, Merck, Celgene, Cue Biopharma, and Loxo Oncology, and research funding from Pfizer, Eli Lilly, Merck, Celgene, Novartis, AstraZeneca, Atara, Blueprint Medicine, CellCeutix, Celldex, Enzychem, Gliknik, BMS, Kura, Medimmune, Exelixis, Innate, Matrix Biomed, and Polaris, outside the submitted work. EKB is a shareholder, executive, and a board member at Geneoscopy LLC. KMC is a shareholder in Geneoscopy LLC.
Clinical Trial
NCT02296684
Funding Statement
We recognize the support of the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, the Clinical Trials Core, the Biostatistics Shared Resource, and the Center for Biomedical Informatics. The Siteman Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842. MG is funded by the National Human Genome Research Institute (NIH NHGRI R00HG007940), OLG by the National Cancer Institute (NIH/NCI K22CA188163, NIH/NCI U01CA209936 and NIH/NCI U24CA237719) and a Cancer Research Foundation Young Investigator Award. RU is funded by the National Institute for Dental and Craniofacial Research (NIH/NIDCR R01DE024403, R01DE027736) and a V Foundation Translational Research Award. Clinical trial support was through a Merck Investigator Studies Program award to RU/DRA.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Co-senior authors
Data Availability
Sequencing data have been deposited in dbGaP (phs001623).
